CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq:CERS) announced today that the Company will
participate in two upcoming investor conferences.
Obi Greenman, Cerus’ president and chief executive officer is
scheduled to attend BTIG’s Annual Healthcare Conference in Snowbird
Utah on Wednesday, February 27, 2019.
Obi Greenman and Kevin Green, Cerus’ vice president finance and chief
financial officer, are scheduled to present a corporate update at
Cowen’s 39th Annual Healthcare Conference in Boston,
Massachusetts on Tuesday, March 12, 2019 at 10:00 a.m. ET.
A live webcast of the presentation from Cowen’s 39th Annual
Healthcare Conference will be available on the Investor Relations page
of the Cerus web site at http://www.cerus.com/ir.
A replay will be available for approximately two weeks following the
completion of the event.
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Tim Lee – Investor Relations Director